Veraxa Biotech is trading 5.8% lower at $1.13 in after-hours trading; no specific catalyst for the decline was reported. - It closed the October 7 regular session at $1.20, up 11.11%. - On October 7, the company announced FDA-aligned preclinical testing methods, including cell-based assays, organ-on-chip systems and computational models. The announcement described potential research benefits, but available reporting does not link it to the after-hours decline. - Trading volume was not reported.